ALTO NEUROSCIENCE INC

Alto Neuroscience’s stock plunged 4.47% as investors grow wary of its clinical‑stage status—highlighting the need for real milestones before market confidence returns.

Alto Neuroscience’s ANRO shares rally 4% amid new pre‑clinical data, sparking investor confidence in its neurobiology‑driven psychiatric pipeline and a potential breakout beyond the 200‑day average.

Alto Neuroscience surges 4.01% as investors recognize its clinical‑stage biopharma potential in mental‑health innovation, driving a 861 m market cap and strong momentum.